Neurocrine Biosciences, Inc. (NBIX) on Decifer

Decifer ranks NBIX number 102 of 270 tracked names on durable business quality.

Why it ranks here

• It earns solid returns on the money it puts to work, around 11% and those returns have been improving and it turns most of its profit into real cash.
• Revenue is growing about 21% a year and profits grew 41% over the past year.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power, with profitability widening as it grows.
• and has the balance sheet to fund its growth.
• And it returns cash to shareholders.
• Revenue growing 21% with profits up 41% and a role as one of 5 specialty-drug franchise owners fund the demand case, though momentum of 10 out of 35 caps timing.

The current read

The evidence on NBIX lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Neuroscience & Mental Health Access: Growing recognition and destigmatization of mental health, combined with new neuro-targeted drugs and neurostimulation devices, is expanding demand for both treatment capacity and therapies.

Read the full NBIX research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.